XY Capital’s Ocular Therapeutix OCUL Stock Holding History

XY Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Hold	37,400	–	–	0.35%	32
2026 Q1	$317K	Buy	+37,400	New	+$356K	0.31%	38

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XY Capital's OCUL Position: Q2 2026 in Review

XY Capital held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 37,400 shares worth $367K. The position accounts for 0.35% of the portfolio, ranked #32.

XY Capital first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

XY Capital held 37,400 shares of Ocular Therapeutix worth $367K as of Q2 2026.
XY Capital left its Ocular Therapeutix share count unchanged in Q2 2026.
Ocular Therapeutix made up 0.35% of XY Capital's portfolio in Q2 2026, its #32 holding.
XY Capital first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on XY Capital's 13F filing for Q2 2026, filed 11 Aug 2026.